Paper Details
- Home
- Paper Details
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.
Author: AimonoYuka, KamoshidaToshiro, KogoMari, KohyamaNoriko, YamamotoToshinori
Original Abstract of the Article :
OBJECTIVE: We investigated factors associated with a reduction in the quality of life and their OR of patients with chronic hepatitis C who underwent ledipasvir/sofosbuvir therapy. METHODS: The subjects were 141 outpatients who had undergone ledipasvir/sofosbuvir therapy under a diagnosis of genoty...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640396/
データ提供:米国国立医学図書館(NLM)
Navigating the Side Effects of Hepatitis C Treatment
The development of effective and well-tolerated treatments for chronic hepatitis C (CHC) has been a significant advancement in medicine. This research examines the factors associated with a reduction in quality of life in patients with CHC who underwent treatment with ledipasvir/sofosbuvir, a highly effective combination therapy.
The authors studied 141 outpatients with genotype I CHC or Child-Pugh A compensated cirrhosis who received ledipasvir/sofosbuvir therapy. They found that an elevated baseline level of alanine aminotransferase (ALT), a liver enzyme, was independently associated with a reduction in quality of life. This finding suggests that patients with higher ALT levels may be more likely to experience a decline in quality of life during ledipasvir/sofosbuvir therapy.
Understanding the Impact of Treatment on Quality of Life
This research highlights the importance of carefully monitoring patients receiving ledipasvir/sofosbuvir therapy for potential side effects, particularly those related to liver function. The finding that elevated ALT levels are associated with a reduction in quality of life underscores the need for individualized treatment plans that address specific patient needs.
Living Well with Hepatitis C: A Collaborative Approach
For patients with CHC, this research emphasizes the importance of open communication with healthcare professionals to discuss potential side effects and to develop strategies for managing these side effects. A collaborative approach, involving the patient, their healthcare provider, and potentially other specialists, can help to ensure optimal treatment outcomes and maintain a good quality of life.
Dr.Camel's Conclusion
This study, like a desert caravan navigating a challenging terrain, highlights the importance of a holistic approach to managing CHC. While ledipasvir/sofosbuvir therapy offers a powerful weapon in the fight against this disease, it's crucial to recognize the potential side effects and to tailor treatment plans to individual needs. With careful monitoring, effective management strategies, and open communication with healthcare providers, patients with CHC can navigate the journey to recovery and maintain a good quality of life.
Date :
- Date Completed 2022-04-01
- Date Revised 2022-11-02
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.